Elimination of clonogenic stem cells from human multiple myeloma cell lines by a plasma cell-reactive monoclonal antibody and complement.
The monoclonal antibody (MoAb) MM4 reacts with human multiple myeloma (MM) cell lines and bone marrow from patients with plasma cell dyscrasias but not with normal peripheral blood or bone marrow cells. Treatment with MM4 and rabbit complement (C') was cytotoxic to the plasma cell-derived cell lines GM 1312, RPMI 8226, and ARH-77, as demonstrated by chromium release microcytotoxicity and trypan blue exclusion assays. The same treatment eliminated greater than 99% of clonogenic myeloma stem cell colony formation of these cell lines, with less than 20% inhibition of normal human bone marrow pleuripotent progenitor colony formation in vitro. As an experimental model to explore the efficacy of MM4 + C' in purging MM-involved bone marrow, normal marrow cells were mixed with RPMI 8226 or GM 1312 cells in the ratio of 90:10 or 50:50 (marrow:myeloma cells). Colony growth assays indicated that MM4 + C' eliminated at least 2 logs of clonogenic myeloma stem cells in both 90:10 and 50:50 preparations, while sparing the majority of normal marrow progenitors (inhibition of CFU-C:10% to 13%; BFU-E:0%). The selectivity of MM4-mediated cytotoxicity may be useful for eliminating myeloma clonogenic stem cells from bone marrow of patients with multiple myeloma.
Tong
A W
AW
Immunology Research Unit, Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas, TX 75246.
Lee
J C
JC
Fay
J W
JW
Stone
M J
MJ
D000911:Antibodies, Monoclonal; D001853:Bone Marrow / Q000473:pathology; D001854:Bone Marrow Cells; D002460:Cell Line; D003165:Complement System Proteins; D003602:Cytotoxicity, Immunologic; D006412:Hematopoietic Stem Cells / Q000166:cytology*; D006801:Humans; D007938:Leukemia / Q000097:blood / Q000473:pathology; D009101:Multiple Myeloma / Q000276:immunology / Q000473:pathology*; D014410:Tumor Stem Cell Assay
D000911:Antibodies, Monoclonal; D003165:Complement System Proteins